Abstract 5864
Background
Cancer is considered a traumatic event that can lead to post-traumatic stress disorder. Significant changes are taking place in the life, body image, lifestyle and social life of the individual diagnosed with cancer. Therefore, they are faced with a psychological and physiological difficult process. In the researches, it was found that the attachment styles that individuals will experience in their lifelong relationships are one of the important predictors of psychological resilience. The aim of our study is to examine the relationship between psychological resilience and adult attachment styles among cancer patient individuals receiving chemotherapy.
Methods
A total of 391 volunteer patients receiving chemotherapy were included from Dr. A.Y. Ankara Oncology Research and Training Hospital and Ankara Güven Hospital in the study. The inventories used in the data collection phase of the study are Relationship Scales Questionnaire, Resilience Scale for Adults and a personal information form that is produced by researcher. Datasare analyzed with SPSS 23.00.
Results
In our results, 285 (73%) of the patients were female and the median age was 53 (20-83). The median endurance score was 130 (49-165). The patients were divided into median values to be less resistant and resistant. The age, gender, marital status, working status, educational status, economic status, who they experienced, who they grew up with, their social support, trust in chemotherapy and dominant attachment styles were compared with univariate analysis. there were four style of attachments; secure, avoidant, fearful, preoccupied. Secure attachment was at half of patients (n = 191,48.8%) while avoidant attachment was at 159 (40.6%) patients. The other attachment styles were seen significantly less.
As a result of multivariate analysis, the patient’s social support is moderate or bad; lack of confidence in chemotherapy, the presence of avoidant or fearful attachment was found to be independent negative factors affecting the resilience of the patient.
Conclusions
Avoidant and fearful attachment have a significant negative impact on the resilience of the patients receiving chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fatma Bugdayci Basal.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2023 - Patients with brain metastases treated with afatinib in clinical practice – results from the prospective non-interventional study GIDEON
Presenter: Eckart Laack
Session: Poster Display session 1
Resources:
Abstract
1613 - Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: initial Phase 1b results
Presenter: David Berz
Session: Poster Display session 1
Resources:
Abstract
2853 - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
Presenter: Petros Christopoulos
Session: Poster Display session 1
Resources:
Abstract
1974 - A Phase II Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients with Activating Epidermal Growth Factor Receptor mutation (EGFRm) from Circulating Tumor DNA (CtDNA)
Presenter: Young-Chul Kim
Session: Poster Display session 1
Resources:
Abstract
3370 - Influence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patients
Presenter: Geerten Veerman
Session: Poster Display session 1
Resources:
Abstract
5900 - PTEN loss as Predictor of Tumor Heterogeneity (TH) and Poor Prognosis in EGFR-mutant Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients (pts) Receiving Tyrosine-Kinase Inhibitors (TKIs).
Presenter: Miriam Ferrara
Session: Poster Display session 1
Resources:
Abstract
1302 - Safety of lorlatinib in subgroups of patients from a phase 1/2 trial
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
1497 - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase 2 ALTA trial
Presenter: Dae Ho Lee
Session: Poster Display session 1
Resources:
Abstract
2349 - The safety assessment of crizotinib and alectinib from real world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).
Presenter: Kei Kunimasa
Session: Poster Display session 1
Resources:
Abstract
1120 - Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the Use Via Expanded Access to Brigatinib (UVEA-Brig) study
Presenter: Silvia Novello
Session: Poster Display session 1
Resources:
Abstract